Short version Beginning in 2023 the FDA made clear it considers most GLP‑1 drugs (semaglutide, tirzepatide and similar peptides) to be biological products that generally should not be “compounded” into copies of FDA‑approved medicines. The agency warned that compounding these biologics can create safety, sterility, potency and labeling risks and may fall outside the limited legal authority for compounding pharmacies. As a result the FDA issued guidance and warning letters and signaled enforcement against compounding that essentially copies approved GLP‑1 products. Many compounding pharmacies stopped offering compounded semaglutide/tirzepatide or scaled back operations; some clinics and operators that continued to offer cheap compounded GLP‑1 injections faced regulatory scrutiny and legal risk. What remains clearly legal: prescribing and dispensing of FDA‑approved GLP‑1 medicines (e.g., Novo Nordisk’s Ozempic and Wegovy (semaglutide), Eli Lilly’s Mounjaro and Zepbound (tirzepatide), and oral semaglutide Rybelsus) through a licensed prescriber and a licensed pharmacy or accredited specialty pharmacy. Certain compounding operations may still be lawful in narrow, specific circumstances, but many routine compounding of copies is not. More detail and practical guidance 1) Why the FDA acted The FDA’s position: many GLP‑1 products are biologics and compounding a product that is essentially a copy of an FDA‑approved biologic is not within normal pharmacy compounding authorities (Sections 503A/503B of the Federal Food, Drug, and Cosmetic Act). Compounding such products raises concerns about sterility, incorrect dosing, impurities, incorrect labeling, lack of stability data, and undermining the regulatory pathway that ensures safety and efficacy. The agency has issued guidance and warnings to state boards and to specific pharmacies/clinics, and it has said it will use enforcement tools where appropriate. 2) Who is operating legally now (general categories) FDA‑approved manufacturers and their supply chains: Novo Nordisk, Eli Lilly and other manufacturers of approved GLP‑1 drugs — these products distributed to pharmacies and specialty pharmacies are fully legal when dispensed on a valid prescription. Licensed retail pharmacies and accredited specialty pharmacies: national chains (CVS, Walgreens, Walmart), and specialty pharmacy providers (for example Accredo, Optum/OptumRx specialty services, Diplomat/Shield HealthCare — note: availability may vary) that dispense FDA‑approved GLP‑1 drugs on prescription are operating legally. Some compounding pharmacies/outsource facilities: a small subset of state‑licensed 503A pharmacies or FDA‑registered 503B outsourcing facilities may still lawfully compound peptides in very limited circumstances (for an individually identified patient, if the compound is not an “essentially a copy” of an approved product, and if state and federal requirements are met). Whether a particular compounder is legally allowed to make a GLP‑1 depends on details (the specific product, how it’s made, prescriptions, state law, and whether FDA has acted). Many compounding pharmacies stopped compounding GLP‑1s to avoid regulatory risk. 3) Red flags and things to avoid Clinics or websites offering cheap “compounded semaglutide/tirzepatide” in bulk without a legitimate individualized prescription. Products imported from overseas or anonymous online vendors with no paperwork or lab testing. Providers refusing to share source/manufacturer, lot numbers, or proof of sterile manufacture/registration if asked. 4) How to verify legality/safety for a specific source Ask your prescriber/pharmacy for the exact product name and manufacturer (e.g., “Wegovy — Novo Nordisk, lot X”). If a compounding pharmacy is involved, ask whether it is a 503B outsourcing facility registered with the FDA or a 503A pharmacy operating under state rules; ask to see current licenses, inspection records, and sterility/quality assurance documentation. Check: FDA’s website for public lists (e.g., registered outsourcing facilities and warning letters) and your state board of pharmacy for actions against pharmacies or clinics. When in doubt, choose an FDA‑approved product dispensed by a licensed pharmacist. Caveat about timing My detailed regulatory knowledge is current through mid‑2024. The FDA’s enforcement posture, court decisions, or state rules could have changed since then. If you want, tell me the name of a specific pharmacy, clinic, or state and I can walk you through how to check its current status (what documents to request, where to look on the FDA/state board websites).
Mentioned in position 9 of 9
Read full answer with sources →